Every three minutes a man finds out he has prostate cancer — the second-leading cause of cancer death in American men. In fact, more than 218,890 cases are expected in 2007, making prostate cancer among men more prevalent than breast cancer among women.
GlaxoSmithKline (GSK) and Sepracor Inc. (Nasdaq: SEPR) announced an agreement for the commercialisation of Sepracor’s eszopiclone product for all markets worldwide (excluding the U.S., Canada, Mexico and Japan).
GlaxoSmithKline announced new results from a large study that demonstrate combination treatment with Avodart® (dutasteride) and the alpha blocker, tamsulosin, provides significantly greater urinary symptom improvement for men with enlarged prostate than either Avodart or tamsulosin monotherapy over 24 months.
The University of Rochester Medical Center (URMC) is participating in a multi-center study of a new medical device to treat epilepsy. The Rochester study is being overseen by neurologists Michel Berg, M.D. and James Fessler, M.D., and neurosurgeons Web Pilcher, M.D., Ph.D. and Jason Schwalb, M.D.
A new book of pocket-charts that will help health workers to identify people at risk of heart attacks and strokes and save lives by prescribing the most appropriate treatment is published by the World Health Organization (WHO).
On Oct. 1, 2007, the BC Ambulance Service (BCAS) will implement a fairer, more streamlined fee structure to ensure most patients pay the same for ambulance transport in B.C., regardless of where they live or the distance they travel, and to eliminate fees for thousands of low income individuals.
Researchers at the University of Texas Medical Branch at Galveston are trying to determine whether a drug already available to heart patients can also be used to delay delivery in expectant mothers with severe pre-eclampsia. If so, this groundbreaking study would give hope to hundreds of thousands of women who experience this life-threatening disorder each year.
Children with amblyopia (commonly known as lazy eye) need only wear an eye patch for three to four hours a day for 12 weeks to improve vision, say researchers in a study published on bmj.com today.
Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL, Swiss Exchange: CRX) announced that its researchers have discovered a monoclonal antibody that is active against H5N1 avian influenza. The studies will be presented at the 5th International Bird Flu Summit scheduled for September 27 and 28 in Las Vegas, Nevada.
The U.S. Food and Drug Administration approved Evista (raloxifene hydrochloride) for reducing the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk for invasive breast cancer.